e-ISSN: Pending
Negative / Null Result ReportOpen accessMicrobiology

VEGFA Isoforms as Pro-Angiogenic Therapeutics for Cerebrovascular Diseases

Amanda Louise White; Gregory Jaye Bix · 2023 · Biomolecules

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

The finding, in one line

However, VEGFA administration in clinical trials has thus far failed to replicate the promising results seen in animal models.

Abstract

Therapeutic angiogenesis has long been considered a viable treatment for vasculature disruptions, including cerebral vasculature diseases. One widely-discussed treatment method to increase angiogenesis is vascular endothelial growth factor (VEGF) A. In animal models, treatment with VEGFA proved beneficial, resulting in increased angiogenesis, increased neuronal density, and improved outcome. However, VEGFA administration in clinical trials has thus far failed to replicate the promising results seen in animal models. The lack of beneficial effects in humans and the difficulty in medicinal trans

Abstract by Amanda Louise White; Gregory Jaye Bix, Biomolecules (2023) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.3390/biom13040702